[Edaily Reporter KYUNG GYEYOUNG ] Centellian24, a derma-cosmetic brand operated by DongKook Pharmaceutical Co.,Ltd.(086450), announced on the 10th that it is expanding its product lineup through major U.S. retail channels to target the North American brick-and-mortar market.
Last month, Centellian24 launched the 100-ml large-size version of its “Madeca Cream Time Reverse” at 200 Costco locations, a membership-based warehouse-style discount store. Following the launch of “Madeca Cream Time Reverse” at Ulta Beauty, the largest beauty retailer in the U.S., last May, the brand expanded its product lineup starting the previous day to include the PDRN, Madeca Matcha, Mela Capture, and Sun Care lines, as well as the beauty DEVICE “Madeca Prime Max.”
In early June, the brand made its debut at 89 Nordstrom locations and on its online store. There, it features the Madeca Cream, PDRN, Madeca Matcha, and Mela Capture lines, as well as beauty DEVICES and the “Madeca Prime Ritual White Pearl.”
A Centellian24 representative stated, “By expanding our collaboration with major U.S. retail channels, we are broadening the opportunities for local consumers to experience Centellian24’s diverse product lineup.” They added, “Madeca Cream is a steady seller on the verge of reaching cumulative sales of 100 million units and ranks as the No. 1 product in the pharmacy beauty category, transcending K-Beauty. We plan to continue strengthening our brand’s position based on our differentiated product quality.”
Centellian24’s Madeca Cream Time Reverse 100 mL, now available at Costco. (Photo courtesy of DongKook Pharmaceutical Co.,Ltd.)
“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
Fashion company Shinwon(009270)continues to show improved performance, driven by strong exports. This is attributed to the company’s expansion of its production and sales infrastructure, particularly …
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…